# US 8,277,777 B2 · Compound having affinity for amyloid

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 8,277,777 B2
- Document ID: US8277777B2
- Status: Granted
- Kind: B2
- Application number: 12/308,715
- Filed: 2007-06-21
- Published: 2010-04-15
- Granted: 2012-10-02
- Earliest claimed: 2006-06-21
- Assignees: Nihon Medi-Physics Co., Ltd.; Ge Healthcare Limited
- Inventors: Shigeyuki Tanifuji; Akio Hayashi; Daisaku Nakamura; Shinya Takasaki; Anthony Eamon Storey; Denis Raymond Christophe Bouvet
- Web page: https://patentgrep.com/patent/US8277777B2

## CPC

- C07D 471/04: Ortho-condensed systems
- A61K 51/0455: {having six-membered rings with one nitrogen as the only ring hetero atom}
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

A compound that has affinity with amyloid, exhibits sufficiently rapid clearance from normal tissues, and is suppressed in toxicity such as mutagenicity is provided, which is represented by the following formula (1): or a salt thereof, wherein R1 is a group selected from hydrogen, hydroxyl group, carboxyl group, sulfate group, amino group, nitro group, cyano group, an alkyl substituent with one to 4 carbon atoms or an alkoxy substituent with one to 4 carbon atoms; R2 is a radioactive halogen substituent; and m is an integer of 0 to 2, and a low-toxic diagnostic agent for Alzheimer's disease comprising a compound represented by the above formula or a salt thereof is also provided.

## Claims

### Claim 1

A compound represented by the following formula (1):
or a salt thereof,
wherein R1 is a group selected from hydrogen, a hydroxyl group, a carboxyl group, a sulfate group, an amino group, a nitro group, a cyano group, an alkyl substituent with 1 to 4 carbon atoms or an alkoxy substituent with 1 to 4 carbon atoms;
R2 is a radioactive halogen substituent; and
m is an integer of 0 to 2.

### Claim 2 (depends on 1)

A compound according to claim 1 or a salt thereof, wherein R2 is selected from the group consisting of from 18F, 76Br, 123I, 124I, 125I or 131I.

### Claim 3 (depends on 1)

A compound according to claim 1 or a salt thereof, wherein R2 is 18F.

### Claim 4

A compound represented by the following formula
or a salt thereof;
wherein R3 is a group selected from hydrogen, a hydroxyl group, a carboxyl group, a sulfate group, an amino group, a nitro group, a cyano group, an alkyl substituent with 1 to 4 carbon atoms, or an alkoxy substituent with 1 to 4 carbon atoms;
R4 is a group selected from a methanesulfonyloxy substituent, trifluoromethane-sulfonyloxy substituent or aromatic sulfonyloxy substituent; and
m is an integer of 0 to 2.

### Claim 5

A low-toxic diagnostic agent for Alzheimer's disease, which comprise a compound represented by the following formula (1):
or a salt thereof,
wherein R1 is a group selected from hydrogen, a hydroxyl group, a carboxyl group, a sulfate group, an amino group, a nitro group, a cyano group, an alkyl substituent with 1 to 4 carbon atoms or an alkoxy substituent with 1 to 4 carbon atoms;
R2 is a radioactive halogen substituent; and
m is an integer of 0 to 2.

### Claim 6 (depends on 5)

A low-toxic diagnostic agent for Alzheimer's disease, according to claim 5, wherein R2 is selected from the group consisting of from 18F, 76Br, 123I, 124I, 125I and 131I.

### Claim 7 (depends on 5)

A low-toxic diagnostic agent for Alzheimer's disease, according to claim 5, wherein R2 is 18F.

### Claim 8 (depends on 1)

A pharmaceutical composition for in vivo imaging of amyloid deposits comprising a compound represented by the formula (1) according to claim 1 or a salt thereof, and a pharmaceutically acceptable carrier or excipient.

### Claim 9 (depends on 1)

A compound represented by the formula (1) according to claim 1 or a salt thereof for use in medicine.

### Claim 10 (depends on 1)

A compound represented by the formula (1) according to claim 1 or a salt thereof for use in in vivo imaging of amyloid deposits.

### Claim 11 (depends on 1)

An in vivo method for detecting amyloid deposits in a subject comprising the steps of:
(a) administering a detectable quantity of a compound represented by the formula (1) according to claim 1 or a salt thereof, and
(b) detecting the binding of the compound or the salt thereof to amyloid deposit in the subject.

### Claim 12 (depends on 11)

A method according to claim 11, wherein step (b) is performed by PET or SPECT imaging.
